All patients
Age < 65y (younger) Age > 65y Asian type cancer location (gastric) cancer location (gastro-esophageal) ECOG 0 ECOG 1 Gender, female Gender, male
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced mGC or mGEJC, anti-CTLA-4 vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CA184-162, 2017 1.54 [0.73; 3.26]
1.54 [0.73 ; 3.26 ] CA184-162, 2017 1 0% 114 NA not evaluable progression or deaths (PFS)detailed results CA184-162, 2017 1.59 [1.20; 2.10]
1.59 [1.20 ; 2.10 ] CA184-162, 2017 1 0% 114 NA not evaluable irORRdetailed results CA184-162, 2017 0.24 [0.03; 2.19]
0.24 [0.03 ; 2.19 ] CA184-162, 2017 1 0% 114 NA not evaluable irPFSdetailed results CA184-162, 2017 1.44 [1.09; 1.91]
1.44 [1.09 ; 1.91 ] CA184-162, 2017 1 0% 114 NA not evaluable TRAE (any grade)detailed results CA184-162, 2017 2.05 [0.90; 4.67]
2.05 [0.90 ; 4.67 ] CA184-162, 2017 1 0% 102 NA not evaluable TRAE (grade 3-4)detailed results CA184-162, 2017 3.03 [0.91; 10.04]
3.03 [0.91 ; 10.04 ] CA184-162, 2017 1 0% 102 NA not evaluable TRAE leading to death (grade 5)detailed results CA184-162, 2017 1.92 [0.55; 6.70]
1.92 [0.55 ; 6.70 ] CA184-162, 2017 1 0% 102 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CA184-162, 2017 1.00 [0.02; 51.28]
1.00 [0.02 ; 51.28 ] CA184-162, 2017 1 0% 114 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CA184-162, 2017 1.59 [0.05; 48.47]
1.59 [0.05 ; 48.47 ] CA184-162, 2017 1 0% 102 NA not evaluable Colitis TRAE (grade 3-4)detailed results CA184-162, 2017 4.94 [0.24; 101.33]
4.94 [0.24 ; 101.33 ] CA184-162, 2017 1 0% 102 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CA184-162, 2017 1.59 [0.05; 48.47]
1.59 [0.05 ; 48.47 ] CA184-162, 2017 1 0% 102 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CA184-162, 2017 8.56 [0.45; 161.00]
8.56 [0.45 ; 161.00 ] CA184-162, 2017 1 0% 102 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CA184-162, 2017 3.24 [0.14; 73.60]
3.24 [0.14 ; 73.60 ] CA184-162, 2017 1 0% 102 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CA184-162, 2017 3.24 [0.14; 73.60]
3.24 [0.14 ; 73.60 ] CA184-162, 2017 1 0% 102 NA not evaluable Myalgia TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Nausea TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CA184-162, 2017 0.19 [0.01; 4.33]
0.19 [0.01 ; 4.33 ] CA184-162, 2017 1 0% 102 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Rash TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CA184-162, 2017 0.79 [0.02; 40.48]
0.79 [0.02 ; 40.48 ] CA184-162, 2017 1 0% 102 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-06 19:07 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 273,122,271,262,260,219,184,272,123,187,185,186,304
- treatments: 504,850,329,558,579,549,868,502,741,556